Skip to main content
    • Aa
    • Aa

Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer

  • Anna L. Stratford (a1), Kristen Reipas (a1), Christopher Maxwell (a1) and Sandra E. Dunn (a1)

Tumour recurrence is one of the biggest challenges in breast cancer management because it affects 25–30% of women with breast cancer and the tumours are often incurable. Women with triple-negative breast cancer (TNBC – lacking expression of the oestrogen receptor, progesterone receptor and the receptor HER2/ERBB2) have the highest rates of early recurrence relative to other breast cancer subtypes. Early recurrence might be due to tumour-initiating cells (TICs), which are resistant to conventional therapies, can remain dormant and can subsequently give rise to secondary tumours. In breast cancer, TICs are identified by the cell-surface markers CD44+/CD24/EpCAM+ and/or possess ALDH1 enzyme activity. This subpopulation has the ability to self-renew, grow as mammospheres and initiate tumour formation. Fuelling the problem of relapse is the fact that chemotherapy and radiation can induce or select for TICs; this was reported in preclinical models and more recently in women being treated for breast cancer. Thus, new therapeutic agents for TNBC are presently being sought to overcome this problem. Here we review the roles of receptor tyrosine kinases, signalling intermediates and transcription factors in sustaining the TIC subpopulation. Particular emphasis is placed on targeting these molecules in order to eliminate and/or prevent the induction of TICs and ultimately reduce the frequency of TNBC recurrence.

Corresponding author
*Corresponding author: Sandra E. Dunn, Department of Pediatrics, Child and Family Research Institute, University of British Columbia, Vancouver, BC, CanadaV5Z 4H4. E-mail:
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1C. Liedtke (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 26, 1275-1281

2T. Sorlie (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98, 10869-10874

3R. Dent (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 13, 4429-4434

4T.M. Phillips , W.H. McBride and F. Pajonk (2006) The response of CD24 − /low/CD44+ breast cancer-intiating cells to radiation. Journal of the National Cancer Institute 98, 1777-1785

5X. Li (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute 100, 672-679

6M.S. Wicha , S. Liu and G. Dontu (2006) Cancer stem cells: an old idea – a paradigm shift. Cancer Research 66, 1883-1890

7M. Al-Hajj (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 100, 3983-3988

8D. Ponti (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Research 65, 5506-5511

9M. Shackleton (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138, 822-829

10S. Chuthapisith (2010) Breast cancer chemoresistance: emerging importance of cancer stem cells. Surgical Oncology 19, 27-32

11C.J. Creighton (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proceedings of the National Academy of Sciences of the United States of America 106, 13820-13825

12S.J. Dylla (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS one 3, e2428

13C.M. Fillmore and C. Kuperwasser (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Research 10, R25

14E. Marangoni (2009) CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancer xenographs. British Journal of Cancer 100, 918-922

15K. To (2010) YB-1 induces expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Research 70, 2840-2851

16L. Jin (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Medicine 12, 1167-1174

17S. Godar (2008) Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 134, 62-73

19G. Stockmans (2008) Triple-negative breast cancer. Current Opinion in Oncology 20, 614-620

21E. Charafe-Jauffret , C. Ginestier and D. Birnbaum (2009) Breast cancer stem cells: tools and models to rely on. BMC Cancer 9, 202-211

22H. Nakshatri , E.F. Srour and S. Badve (2009) Breast cancer stem cells and intrinsic subtypes: controversies rage on. Current Stem Cell Research and Therapies 4, 50-60

23M. Shipitsin (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273

24C. Ginestier (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567

25H. Korkaya (2008) HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 27, 6120-6130

26H. Nalwoga (2010) Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer. British Journal of Cancer 102, 369-375

27G. Dontu and M.S. Wicha (2005) Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. Journal of Mammary Gland Biology and Neoplasia 10, 75-86

28M.R. Finkbeiner (2009) Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28, 1421-1431

29E. Lim (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine 15, 907-913

30M.L. Asselin-Labat (2006) Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute 98, 1011-1014

31P. Eirew (2008) A method for quantifying normal human mammary epithelial cells with in vivo regenerative ability. Nature Medicine 14, 1384-1389

33J.E. Visvader (2009) Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes and Development 23, 2563-2577

35A.K. Croker (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. Journal of Cellular and Molecular Medicine 13, 2236-2252

36C. Sheridan (2006) CD44+/CD24 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Research 8, R59

38R. Liu (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. New England Journal of Medicine 356, 217-226

39P.B. Gupta (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 1-15

41A.L. Stratford (2007) Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer providing a potential target for therapy. Breast Cancer Research 9, R61

42M.C.U. Cheang (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research 14, 1368-1376

43E. Marangoni (2007) A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clinical Cancer Research 13, 3989-3998

44G. Farnie (2007) Novel cell culture technique for primary ductal carcinoma in situ: role of notch and epidermal growth factor receptor signaling pathways. Journal of the National Cancer Institute 99, 616-627

45A. Di Leo (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. Journal of Clinical Oncology 26, 5544-5552

47M.D. Green (2009) Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Annals of Oncology 20, 1813-1817

48A. Polychronis (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncology 6, 383-391

49N. Normanno (2008) Breast cancer cells with acquired resistance to EGFR tyrosine kinase inhibitor gefitinib show persistant activation of MAPK signaling. Breast Cancer Research and Treatment 112, 25-33

51B. Corkery (2009) Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Annals of Oncology 20, 862-867

52K.A. Hoadley (2007) EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics 8, 258

54T. Nielsen (2004) Expression of the insulin-like growth factor-1 receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17 allylamino 17-demethoxy geldanamycin. Cancer Research 64, 286-291

55J.H. Law (2008) Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Research 68, 10238-10246

56A. Klinakis (2009) Igf1r as a therapeutic target in a mouse model of basal-like breast cancer. Proceedings of the National Academy of Sciences of the United States of America 106, 2359-2364

57J.M. Carboni (2005) Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Research 65, 3781-3787

58H.-G. Kim (2007) Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-ĸB and snail. Molecular and Cellular Biology 27, 3165-3175

59S.E. Moody (2005) The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell 8, 197-209

60R.A. Jones (2009) Reversibility and recurrence of IGF-IR-induced mammary tumors. Oncogene 28, 2152-2162

61R.L. Camp , E.B. Rimm and D.L. Rimm (1999) Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma. Cancer 86, 2259-2265

62R.A. Ghoussoub (1998) Expression of c-met is a strong independent prognostic factor in breast carcinoma. Cancer 82, 1513-1520

63A.L. Welm (2005) MET and MYC cooperate in mammary tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 102, 4324-4329

64V. Orian-Rousseau (2002) CD44 is required for two consecutive steps in HGF/c-MET signaling. Genes and Development 16, 3074-3086

65C.R. Graveel (2009) Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America 106, 12909-12914

66M.G. Ponzo (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proceedings of the National Academy of Sciences of the United States of America 106, 12903-12908

67P. Comoglio , S. Giordano and L. Trusolino (2008) Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nature Reviews Drug Discovery 7, 504-516

69H. Tsuda (2005) Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with ‘stem-cell-like’ features. Cancer Science 96, 333-339

70V. Levina (2010) Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Research 70, 338-346

71T.O. Nielsen (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast cancer. Clinical Cancer Research 10, 5367-5374

72D.J. Renouf , L. Wilson and C.D. Blanke (2009) Successes and challenges in translational research: the development of targeted for gastrointestinal stromal tumours. Clinical Cancer Research 15, 3908-3911

73M.C. Heinrich (2003) Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology 21, 4342-4349

74J. Zhou (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proceedings of the National Academy of Sciences of the United States of America 104, 16158-16163

75Y. Eralp (2008) MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Annals of Oncology 19, 669-674

76R.-H. Chen , C. Abate and J. Blenis (1993) Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proceedings of the National Academy of Sciences of the United States of America 90, 10952-10956

77G.J. Schouten (1997) IKappaB alpha is a target for the mitogen-activated 90 kDa ribosomal S6 kinase. EMBO Journal 16, 3133-3144

78P.B. Joel (1998) pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Molecular and Cellular Biology 18, 1978-1984

79A.L. Stratford (2008) Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Research 10, R99

80A. Shimamura (2000) Rsk1 mediates a MEK-MAP kinase cell survival signal. Current Biology 10, 127-135

81R. Anjum (2005) The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Current Biology 15, 1762-1767

82M.D. Larrea (2009) RSK1 drives p17Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proceedings of the National Academy of Sciences of the United States of America 106, 9268-9273

84A. Cuadrado and A.R. Nebreda (2007) New insights into RSK activation and hematopoietic cancer. Cancer Cell 12, 187-189

86W. Xian (2009) Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Research 69, 2244-2251

87Y.-Y. Cho (2007) Ribosomal S6 kinase 2 is a key regulator in tumor promoter-induced cell transformation. Cancer Research 67, 8104-8112

88G.P. Sapkota (2007) BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Journal of Biochemistry 401, 29-38

89M.S. Cohen , H. Hadjivassiliou and J. Taunton (2007) A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nature Chemical Biology 3, 156-160

90C.G. Kleer (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 100, 11606-11611

91M.-L. Suvà (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Research 69, 9211-9218

92M.E. Gonzalez (2009) Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene 28, 843-853

93S. Bergmann (2005) YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Research 65, 4078-4087

94R.C. Bargou (1997) Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nature Medicine 3, 447-450

95M. Kuwano (2003) The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Science 94, 9-14

96B.W. Sutherland (2005) Akt phosphorylates the Y-box binding 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24, 4281-4292

98J. Wu (2006) Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Research 66, 4872-4879

99A. Astanehe (2009) The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 28, 2406-2418

100G. Habibi (2008) Re-defining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Research 10, R86

101C. Lee (2008) Targeting YB-1 in HER-2 over-expressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Research 68, 8661-8666

102A.D. Judge (2009) Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. Journal of Clinical Investigation 119, 661-673

103S.C. Semple (2010) Rational design of cationic lipids for siRNA delivery. Nature Biotechnology 28, 172-176

104S.A. Narod and W.D. Foulkes (2004) BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer 4, 665-676

105O.A. Stefansson (2009) Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Research 11, R47

106W.D. Foulkes (2004) BRCA1 functions as a breast stem cell regulator. Journal of Medical Genetics 41, 1-5

107A.L. Bane (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. American Journal of Surgical Pathology 31, 121-128

109N.C. Turner and J.S. Reis-Filho (2006) Basal-like breast cancer and BRCA1 phenotype. Oncogene 25, 5846-5853

110A. McCarthy (2007) A mouse model of basal-like breast carcinoma with metaplastic elements. Journal of Pathology 211, 389-398

111C.X. Deng and R.H. Wang (2003) Roles of BRCA1 in DNA damage repair: a link between development and cancer. Human Molecular Genetics 12 Spec No 1, R113-R123

112H.E. Bryant (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917

113H. Farmer (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921

114B. Evers (2008) Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clinical Cancer Research 14, 3916-3925

115S. Rottenberg (2008) High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proceedings of the National Academy of Sciences of the United States of America 105, 17079-17084

116T. Byrski (2009) Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. Journal of Clinical Oncology 28, 375-379

117L.A. Carey (2010) Targeted chemotherapy? Platinum in BRCA1-dysfuntional breast cancer. Journal of Clinical Oncology 28, 361-363

118B. Evers (2010) A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clinical Cancer Research 16, 99-108

119P.C. Fong (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. New England Journal of Medicine 361, 123-134

120S. Furuta (2005) Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America 102, 9176-9181

121S. Liu (2008) BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of the National Academy of Sciences of the United States of America 105, 1680-1685

122C. Ginestier , S. Liu and M.S. Wicha (2009) Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell 5, 229-230

123O. Gautschi (2008) Aurora kinases as anticancer drug targets. Clinical Cancer Research 14, 1639-1648

124S. Chang (2009) Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations. Journal of Clinical Investigation 119, 3160-3171

125M. Ouchi (2004) BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. Journal of Biological Chemistry 279, 19643-19648

126S. Sankaran (2007) Aurora-A kinase regulates breast cancer associated gene 1 inhibition of centrosome-dependent microtubule nucleation. Cancer Research 67, 11186-11194

127B.T. Hennessy (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Research 69, 4116-4124

128G. Honeth (2008) The CD44+/CD24− phenotype is enriched in basal-like breast tumors. Breast Cancer Research 10, R53

129T. Tanei (2009) Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancer. Clinical Cancer Research 15, 4234-4241

130K. Kai (2010) Breast cancer stem cells. Breast Cancer 17, 80-85

131J.P. Sleeman and N. Cremers (2007) New concepts in breast cancer metastasis: tumour initiating cells and the microenvironment. Clinical and Experimental Metastasis 24, 707-715

A.R. Tan and S.M. Swain (2008) Therapeutic strategies for triple-negative breast cancer. The Cancer Journal 14, 343-351

M. Shipitsin and K. Polyak (2008) The cancer stem cell hypothesis: in search of definitions, markers and relevance. Laboratory Investigation 88, 459-463

P. Diamandis (2007) Chemical genetics reveals a complex functional ground state of neural stem cells. Nature Chemical Biology 3, 268-273

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *